dr. fakih on durvalumab and tremelimumab in crc
Published 5 years ago • 93 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:59
dr. fakih on future directions in crc
-
1:30
dr. fakih on advances in liver-directed therapies in crc
-
1:14
dr. fakih discusses the utility of immunoscore in crc
-
1:08
dr. fakih on the safety profile of amg 510 in kras g12c-mutated crc
-
1:20
dr. fakih on immunotherapy in mss colon cancer
-
1:39
dr. fakih on the use of regional therapy in colorectal cancer
-
1:33
dr. balar on results of durvalumab plus tremelimumab in bladder cancer
-
0:42
dr. fakih on anti-angiogenesis versus anti-egfr therapy in colon cancer
-
1:14
dr. fakih on ras mutations in colon cancer
-
0:53
copy of dr. fakih on the use of regional therapy in colorectal cancer
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
1:04
marwan g. fakih, md, on combining regorafenib checkpoint inhibition in advanced crc
-
1:08
dr. bazhenova on the pacific trial with durvalumab in nsclc
-
6:37
caspian trial: durvalumab and chemotherapy in es-sclc
-
2:33
emerald-3: tremelimumab durvalumab with or without lenvatinib combined with tace in hcc
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
4:11
continuum of care in metastatic colorectal cancer
-
2:07
extensive-stage sclc: potential in the caspian trial
-
1:10
dr. powles discusses the future of durvalumab in bladder cancer